BMCS BioTech Medics Inc (PK)

BioTech Medics, Inc. (PINKSHEETS: BMCS) announced today that BCC Research of Massachusetts advised BioTech Medics, Inc. that its patented proprietary SHBAN(TM) Antiviral Hand Sanitizer Solution was one of the antiseptic products cited in their major research study.

Increasing consumer awareness of the dangers of H5N1 Avian Bird Influenza and H1N1 (Swine) Influenza A as well as staph infections together with various bacteria and fungus microbes has led to an increased use of hand sanitizers.

The BCC Report highlights that the global market for antiseptics and disinfectants reached $3.1 billion in 2008 and is projected to reach $4.9 billion by 2013 at a compound annual growth rate of 9.6%.

BioTech is now poised to capture a portion of the worldwide antiviral/antimicrobial solution market. BioTech has been negotiating with various interested parties for acquiring a SHBAN Distributorship. BioTech will be announcing soon the establishment of its first offshore Distributorship.

SHBAN is a bio-degradable product superior to most anti-viral and anti-bacterial disinfectants because 1) SHBAN is longer lasting, SHBAN does not evaporate within 15 seconds after application and cease working (like alcohol gels); 2) SHBAN is non-toxic when used as directed on humans and animals; 3) SHBAN is non-staining, non-bleaching; 4) SHBAN is non-flammable and 5) SHBAN has no harmful or toxic odors. Most hand sanitizer products cannot make all of these claims.

BioTech currently sells a 3 oz SHBAN(TM) Go Anywhere Hand Atomizer Spray Bottle that complies with TSA carry-on travel regulations. SHBAN sales are up significantly in 2009. BioTech is releasing soon 1 oz and 16 oz bottles together with SHBAN Hand Wipe Towelettes.

In 2007 BioTech conducted an independent study to determine the efficacy of virucidal SHBAN against Avian H5N1 Influenza NIBRG-14 Virus. BioTech reported that the SHBAN Solution had clinically proven its anti-viral properties and had topically killed the Avian Influenza virus. Significantly, SHBAN was proven non-toxic with "no cytotoxicity observed on the MDCK cell line after treatment." SHBAN efficacy is being tested on H1N1 Swine Influenza at this time.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Tom Wood Sr. V.P. Sales Phone 972-849-3782